.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,091,169

« Back to Dashboard

Claims for Patent: 5,091,169

Title: Dipyridoxyl phosphate NMRI contrast agent compositions
Abstract:N,N'-bis-(pyridoxal-5-phosphate)-alkylenediamine-N,N'-diacetic acids, N,N'-bis-(pyridoxal-5-phosphate)-1,2-cycloalkylenediamine-N,N'-diacetic acids, and N,N'-bis-(pyridoxal-5-phosphate)-1,2-arylenediamine-N,N'-diacetic acids, the corresponding monophosphate compounds and monoacetic acid compounds, and their salts and esters form stable, highly soluble chelates with paramagnetic metal ions, and are highly effective NMRI contrast agents. Preferred contrast agents are paramagnetic ion chelates of N,N'-bis-(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid, N,N'-bis-(pyridoxal-5-phosphate)trans-1,2-cyclohexylenediamine-N,N'diaceti c acid, N,N'-bis-(pyridoxal-5-phosphate)trans-1,2-arylenediamine-N,N'-diacetic acid, and the soluble calcium salts thereof. Novel intermediates for forming these compounds are N,N'-bis(pyridoxal-5-phosphate)alkylenediimines, N,N'-bis(pyridoxal-5-phosphate)alkylenediamines, N,N'-bis(pyridoxal-5-phosphate)-1,2-cycloalkylenediimines, N,N'-bis(pyridoxal-5-phosphate)-1,2-cycloalkylenediamines, N,N'-bis(pyridoxal-5-phosphate)-1,2-arylenediamines, and the corresponding monophosphate compounds.
Inventor(s): Rocklage; Scott M. (Saratoga, CA), Quay; Steven C. (Los Altos Hills, CA)
Assignee: Salutar, Inc. (Sunnyvale, CA)
Application Number:07/370,429
Patent Claims: 1. An NMRI contrast medium composition consisting essentially of a chelate of a compound of the formula I with a metal ion having an atomic number within the range of 21 to 29, 42, 44 or 58-70 and a pharmaceutically acceptable, compatible excipient: ##STR9## wherein: R is hydrogen or ##STR10## R.sub.1 is hydrogen or ##STR11## with the proviso that at least one of R and R.sub.1 is other than hydrogen;

R.sub.5 and R.sub.6 are each, independently, hydroxy, alkoxy having from 1 to 18 carbons, hydroxy-substituted alkoxy having from 1 to 18 carbons, amino, or alkylamido having from 1 to 10 carbons;

R.sub.3 is alkylene having from 1 to 8 carbons, 1,2-cycloalkylene having from 5 to 8 carbons, or 1,2-arylene having from 6 to 10 carbons;

R.sub.4 is hydrogen, hydroxymethyl, alkyl having from 1 to 6 carbons, or ##STR12## each R.sub.7 is, independently, hydrogen, hydroxy-substituted alkyl having from 1 to 18 carbons, or aminoalkyl having from 1 to 18 carbons; or a physiologically biocompatible inorganic or organic cation salt of said chelating compound.

2. An NMRI contrast medium composition of claim 1 wherein R is ##STR13## and R.sub.1 is ##STR14##

3. An NMRI contrast medium composition of claim 2 wherein R.sub.5 and R.sub.6 are each, individually, hydroxy, alkoxy having from 1 to 8 carbons, amino or alkylamido having from 1 to 8 carbons.

4. An NMRI contrast medium composition of claim 3 wherein R.sub.5 and R.sub.6 are hydroxy or a salt thereof.

5. As a NMRI contrast medium composition of claim 4, N,N'-bis-(pyridoxal-5-phosphate ethylenediamine-N,N'-diacetic acid or a salt thereof.

6. An NMRI contrast medium composition of claim 1 wherein R.sub.3 is alkylene having from 2 to 6 carbons.

7. An NMRI contrast medium composition of claim 1 wherein R.sub.3 is cyclohexyl.

8. As a NMRI contrast medium composition of claim 7, N,N'-bis-(pyridoxal-5-phosphate)-trans-1,2-cyclohexyldiamine-N,N'-diacetic acid or a salt thereof.

9. An NMRI contrast medium composition of claim 1 wherein the metal ion is selected from the group consisting of chromium(II), manganese(II), iron(III), iron(II), cobalt(II), nickel(II), copper(II), praseodymium(III), neodymium(III), samarium(III), ytterbium(III), gadolinium(III), terbium(III), dysprosium(III), holmium(III) and erbium(III).

10. An NMRI contrast medium composition of claim 9 comprising a calcium salt of the chelate.

11. An NMRI contrast medium composition of claim 10 comprising a calcium salt of the chelate wherein the molar ratio of calcium to chelating compound is from 0.05 to 1.0.

12. An NMRI contrast medium composition of claim 11 comprising a calcium salt wherein the molar ratio of calcium to chelating compound is from 0.1 to 0.5.

13. An NMRI contrast medium composition of claim 9 wherein the metal ion is manganese(II) ion.

14. An NMRI contrast medium composition of claim 9 wherein the compound is N,N'-bis-(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid, N,N'-bis-(pyridoxal-5-phosphate)-trans-1,2-cyclohexyl diamine-N,N'-diacetic acid, or a salt thereof.

15. An NMRI contrast medium composition of claim 14 comprising a calcium salt.

16. An NMRI contrast medium composition of claim 15 comprising a calcium salt, wherein the molar ratio of calcium to chelating compound is from 0.05 to 1.0.

17. An NMRI contrast medium composition of claim 16 comprising a calcium salt, wherein the molar ratio of calcium to chelating compound is from 0.01 to 0.5.

18. An NMRI contrast medium composition of claim 9 wherein the concentration of chelate salt in the medium is from 0.001 to 5.0 moles per liter.

19. An NMRI contrast medium composition of claim 18 wherein the concentration of chelate salt in the medium is from 0.1 to 0.5 moles per liter.

20. An NMRI contrast medium composition of claim 19 wherein each R.sub.7 is, independently, hydrogen.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc